Articles

CAR-T Cell Therapy Sequence Listing Requirements and Challenges

CAR-T cell therapy sequence listing has become one of the most discussed topics in the biopharmaceutical and patent law landscape. As CAR-T (Chimeric Antigen Receptor T-cell) therapies continue to revolutionize cancer treatment, the legal and regulatory frameworks surrounding their intellectual property protection are growing more complex. Whether you are a patent attorney, a biotech researcher, or a regulatory affairs professional, understanding how sequence listing requirements apply to CAR-T technologies is no longer optional. It is essential. This article breaks down everything you need to know in a clear, straightforward way, so you can navigate this space with confidence.

What Is CAR-T Cell Therapy and Why Does Sequence Listing Matter?

CAR-T cell therapy is a form of immunotherapy where a patient’s own T-cells are genetically engineered to express chimeric antigen receptors (CARs) on their surface. These receptors allow the T-cells to recognize and attack specific cancer cells with remarkable precision. Therapies like Kymriah and Yescarta have already demonstrated dramatic results in treating blood cancers such as leukemia and lymphoma.

At the heart of every CAR-T construct lies a series of biological sequences: nucleotide sequences encoding the CAR receptor, amino acid sequences of the single-chain variable fragment (scFv), transmembrane domains, co-stimulatory domains, and signaling components. When a company files a patent application for a CAR-T technology, all these sequences must be formally disclosed in a structured format called a “sequence listing.”

A sequence listing is a standardized, machine-readable document that accompanies a patent application and contains all nucleotide and amino acid sequences of 10 or more residues that are referenced in the patent claims or description. Without a proper sequence listing, a patent application can face serious procedural setbacks, or worse, rejection.

The car-t cell therapy sequence listing process is not merely a formality. It is a legally binding disclosure that affects claim scope, patent enforceability, and competitive positioning.

Key Requirements for CAR-T Cell Therapy Sequence Listing

Understanding the regulatory requirements is the first step toward getting it right. The rules have evolved significantly in recent years, and staying current is critical.

WIPO ST.26: The New Global Standard

The most significant recent change in sequence listing requirements is the transition from WIPO ST.25 to WIPO ST.26, which became mandatory in July 2022 for most patent offices worldwide, including the USPTO, EPO, and JPO.

Under WIPO ST.26, car-t cell therapy sequence listings must be submitted in XML format, replacing the older ASCII text format used under ST.25. This shift has major implications for CAR-T patent applications because:

XML-based submissions require specialized software tools such as WIPO Sequence or third-party platforms.
Sequence identifiers (SEQ ID NOs) must be linked precisely to claims and descriptions in a traceable manner.
Biological sequences with fewer than 10 nucleotides or 4 amino acids are explicitly excluded from listing requirements, but anything above these thresholds must be included.
Modified nucleotides and non-standard amino acids common in CAR constructs must be annotated using controlled vocabulary defined by WIPO ST.26 Annex I and II.
Feature annotations are now mandatory for many sequence types, including CDRs (Complementarity Determining Regions) used heavily in scFv domains of CAR-T constructs.

USPTO-Specific Rules

For U.S. filings, the USPTO has adopted ST.26 with additional procedural requirements. The sequence listing must be submitted as a separate XML file through EFS-Web or Patent Center. Importantly, the sequence listing forms part of the specification, and any inconsistency between sequences in the description and those in the listing can result in a lack of written description rejection under 35 U.S.C. § 112.

EPO-Specific Rules

The European Patent Office requires car-t cell therapy sequence listing submissions to comply with Rule 30 EPC. Applicants must file the sequence listing on the filing date to avoid surcharges or loss of filing date in some circumstances. The EPO also places heavy emphasis on ensuring that sequences disclosed in examples are listed with correct feature annotations, particularly for therapeutic antibody fragments used as targeting domains in CAR constructs.

Major Challenges in CAR-T Cell Therapy Sequence Listing

Despite clear guidelines, the car-t cell therapy sequence listing process presents unique challenges that even experienced patent professionals find difficult to navigate.

1. Complexity of CAR Construct Architecture

CAR-T constructs are inherently multi-domain proteins. A typical CAR includes:

An extracellular antigen-binding domain (usually an scFv derived from a monoclonal antibody)
A hinge region
A transmembrane domain
One or more co-stimulatory domains (e.g., CD28, 4-1BB)
An intracellular signaling domain (e.g., CD3 zeta chain)

Each of these components may contain independently listable sequences. In a single patent application, a company might need to disclose dozens or even hundreds of SEQ ID NOs covering heavy chain variable regions, light chain variable regions, CDR sequences, full-length CAR polynucleotides, and encoded polypeptides. Managing this volume of sequences without errors requires meticulous quality control.

2. Inconsistencies Between Priority Applications

Many CAR-T patent families begin as a provisional application in the U.S. and later proceed to PCT or national phase applications. One of the most common and damaging errors in car-t cell therapy sequence listing practice is inconsistency between sequences filed in the priority application and those in later filings.

If a sequence is added or modified in a continuation or PCT application, it may not receive the benefit of the earlier priority date, potentially opening up the invention to prior art challenges or intervening third-party filings. This is particularly damaging in the fast-moving CAR-T space, where competitors are filing at an aggressive pace.

3. Handling Codon-Optimized Sequences

Most commercial CAR-T therapies use codon-optimized polynucleotide sequences to enhance expression in human cells. These optimized sequences differ from the naturally occurring sequences on which the CAR is based. A common challenge is determining whether both the native sequence and the codon-optimized variant must be listed separately. Under WIPO ST.26, if both sequences are referenced in the specification or claims, both must be included in the sequence listing with individual SEQ ID NOs. Failure to do so can result in an incomplete disclosure.

4. Software and Technical Compliance

Generating an ST.26-compliant XML file for a complex CAR-T patent is technically demanding. Common technical issues include:

Incorrect feature key assignments for modified residues
Missing or improperly formatted organism qualifiers
Sequence length mismatches between the XML and the description
Failure to validate the XML file before submission

These errors often go unnoticed until an office action is issued, at which point correction can be costly and time-consuming.

Best Practices for Navigating CAR-T Cell Therapy Sequence Listing Successfully

Proactive planning is the most effective way to handle car-t cell therapy sequence listing requirements. Here are the strategies that work:

Start Early: Begin sequence listing preparation during the drafting phase, not after the application is complete. Identify every sequence referenced in the claims and description before filing.

Use Validated Software: Tools like WIPO Sequence, PatentIn (legacy), or commercial platforms specifically designed for ST.26 compliance reduce the risk of technical errors.

Conduct a Cross-Reference Audit: Ensure every SEQ ID NO mentioned in the specification corresponds exactly to the sequence in the listing, and vice versa. Even a single mismatch can generate an office action.

Engage Sequence Listing Specialists: Given the complexity of CAR-T constructs, many law firms now employ dedicated bioinformatics specialists who manage sequence listing preparation alongside the legal team.

Track Sequence Changes Across Filings: Maintain a master sequence database for each patent family to ensure consistency across all related applications, including continuations, divisionals, and international filings.

Prepare for Post-Grant Challenges: In inter partes review (IPR) proceedings or opposition proceedings at the EPO, sequence disclosures are often scrutinized. Ensure your car-t cell therapy sequence listing supports the full scope of your claims.

The Business and Competitive Implications

The stakes in CAR-T intellectual property are enormous. The global CAR-T cell therapy market is projected to exceed $25 billion by the early 2030s. A single flawed sequence listing can cost a company its patent rights over a blockbuster therapy, open the door to generic competition, or trigger expensive litigation.

Companies like Novartis, Gilead/Kite, and Bristol Myers Squibb have built extensive patent portfolios around CAR-T technologies, and competitors are watching every filing closely. Proper car-t cell therapy sequence listing is not just a compliance checkbox. It is a strategic business asset that must be managed with the same rigor as clinical trial data.

Conclusion

The requirements and challenges surrounding car-t cell therapy sequence listing are real, complex, and constantly evolving. From understanding WIPO ST.26 XML formatting rules to managing codon-optimized sequences and maintaining consistency across global patent families, the margin for error is narrow. But with the right knowledge, the right tools, and a proactive approach, these challenges are entirely manageable.

As CAR-T therapies move further into the oncology mainstream and expand into new indications like solid tumors and autoimmune diseases, the volume and complexity of related patent filings will only increase. Staying ahead of sequence listing requirements today means protecting your innovation tomorrow.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.